Introduction ▼ Molecular genetic studies of familial pain syndromes have shown that voltage-gated sodium channels play a major role in the pathogenesis of painful neuropathies. Several channels have been able to be located throughout the nervous system and familial pain syndromes are associated with mutations in one of these channels [ 9 ] . Sodium channels are made up of a single α-subunit and multiple ß-subunits. Several mutations in the SCN9A gene, which encodes the α-subunit of sodium channel Na V 1.7, have been discovered in patients with primary erythromelalgia [ 10 , 23 ] . It has been demonstrated that these mutations cause both a hyperpolarizing shift in activation and slowed deactivation [ 5 ] . This channel is expressed primarily in nociceptors of the dorsal Abstract ▼ Erythromelalgia is a rare disorder characterized by recurrent pain attacks, swelling and redness in the distal extremities. The primary forms of the disorder are caused by mutations in voltagegated sodium channels. Treatment is diffi cult and controlled therapeutic studies off er little to no guidance. We report on a 12-year-old boy and his fi rst occurrence of primary erythromelalgia. Genetic fi ndings for mutations in the SCN9A gene, which encodes for the α-subunit of sodium channel Na V 1.7, were negative. Although initial treatment with sodium nitroprusside was ineffective, subsequent medication with lidocaine and mexiletine, in combination with gabapentin, was successful. Despite negative fi ndings for mutations in the sodium channels, the use of sodium channel blockers should be considered in these patients. cological treatment of the pain disorder is often diffi cult. Controlled studies off ering treatment recommendations are lacking. The 2 most commonly used classes of drugs for this purpose are sodium channel blockers (e. g., lidocaine, mexiletine or carbamazepine) and vasodilators such as sodium nitroprusside. Alleviation of pain without drugs is usually achieved only by continuously cooling the aff ected extremities with freezing water or ice.
Zusammenfassung
We report on a 12-year-old boy who suff ered from excruciating pain in his distal extremities due to primary erythromelalgia. Key to the patient's diagnosis was the observation that, at least in the early stages, symptoms were alleviated only by immersion of his hands and feet in ice water. Vasodilators showed no eff ect, but treatment with sodium channel blockers was successful, even though no mutations were found in the SCN9A gene.
Case report ▼
A 12-year-old boy in our outpatient clinic presented with a 1-month history of intermittent pain located in the interphalangeal joints of both feet -a pain he experienced for the fi rst time after playing soccer on a hot summer day. During the 5 days prior to presentation, this pain slowly increased, associated swelling developed, and the aff ected areas spread to involve fi ngers as well as feet. The patient reported neither redness nor warmth in the aff ected areas and had no other symptoms or complaints. His past medical history, apart from an upper respiratory infection 4 weeks prior to commencement of the pain, was unremarkable. Upon physical examination, he presented with excruciating pain when touched on the phalanges of both hands and feet. However, no swelling, redness or warmth was apparent. Although his blood pressure was elevated (i. e., 140/60 mmHg), further examination of the patient was without pathological fi ndings and initial laboratory work-up did not show any pathological changes. The patient was sent home with presumptive post-infectious arthritis and treated with ibuprofen and paracetamol. Three days later, he returned due to aggravated paroxysmal pain without paresthesias. The patient was no longer able to walk due to excruciating pain. Physical fi ndings were unchanged. Apart from arterial hypertension, no other signs of autonomous dysfunctions were present, (no dysrhythmia, orthostatic hypotension, paralytic ileus, bladder dysfunction or abnormal sweating). Diff erential work-up revealed normal results for blood count and glucose, as well as negative fi ndings for rheumatoid factors, antinuclear antibodies, HLA-B27, anti-streptolysin O, antiphospholipid antibodies, antineutrophil cytoplasmic antibodies, and borrelia antibodies. No evidence of complement system activation was detected. MRI studies were normal without signs of arthritis, tendovaginitis, myositis or osteomyelitis. Treatment with peripheral analgesics, including acetylsalicylic acid and high-dose piritramide, did not alleviate any pain. The only therapy that succeeded in reducing the pain was immersing the aff ected extremities in freezing water. Based on this fi nding, a clinical diagnosis of primary erythromelalgia was made. Direct sequencing of exons 1 to 26 and the fl anking intron sequences revealed no mutation in the coding region of the SCN9A gene. A skin punch biopsy showed no infl ammatory changes. Normal density of intraepidermal nerve fi bers by fl uorescence immunohistochemistry, using the antibody PGP9.5, excluded a smallfi ber axonopathy, The clinical features of allodynia and hyperalgesia in our patient might be explained by an acute small-fi ber neuropathy, which is often associated with erythromelalgia in children [ 4 ] , but other common clinical fi ndings such as a burning pain character, numbness, tickling paresthesias and reduced pinprick and thermal sensation were absent in our patient. Additionally, small-fi ber neuropathy usually has a chronic course and lasts many years. A sensory variant of a Guillain-Barré syndrome was determined to be unlikely, due to the absence of paresthesias, the lack of diminished or absent ankle refl exes, and the involvement of the hands without ascension of the sensory defects beyond the feet. Fabry's disease was ruled out by normal activity of L-D-galactosidase in serum and in polymorphonuclear leukocytes. The patient's elevated blood pressure did not respond to nifedipine. Given the observed ineff ectiveness of nifedipine, and based upon reports of successful pain control through use of vasodilators, therapy was begun with sodium nitroprusside. A normal heart function and a regular ECG were confi rmed in advance. While closely monitoring vital signs, in particular cardiovascular parameters, infusion was titrated to a maximal dosage of 6 mcg/ kg/min. Since no change in symptoms could be documented after 5 days of therapy, we replaced nitroprusside with lidocaine, a sodium channel blocker. We started with 16.5 mcg/kg/min and titrated it to a maximum dose of 60 mcg/kg/min. Lidocaine levels under this dosage were within the recommended therapeutic range of 2-5 mg/l. Reduction of overall pain levels was achieved and ice water treatment for breakthrough pain could be reduced from an initial 20 h per day to 1 h per day. Therapy with mexiletine, an oral sodium channel stabilizer, was commenced with 2 mg/kg per day and increased to 10 mg/kg/day over a 3-week period, while reducing lidocaine in parallel. As a supportive drug for treatment of neuropathic pain, gabapentin, at a dose of 15 mg/kg per day, was started the same day as mexiletine. Intravenous lidocaine was stopped after 5 weeks. Prolonged pain experience led to a secondary pain syndrome. Psychological interventions reduced the conditioned anxiety response to pain. Our patient was noted to be hypertensive for his age. Urine catecholamine metabolites were within normal range. Aside from the period of sodium nitroprusside therapy, blood pressure stabilization -without complete normalization -was achieved only through a combination of amlodipine, ramipril and prazosine. After 6 weeks of hospital treatment, the patient was able to be discharged on mexiletine, gabapentin and antihypertensive triple medication. At this stage, however, he was not completely free of pain. Only over the course of the following 6 weeks did the patient become symptom-free. His medication was tapered down accordingly. The absence of pain was accompanied by a normalization of his blood pressure. Gabapentin was discontinued after a total of 6 weeks of treatment, and mexiletine after 4 months of therapy. 8 months after stopping all his medications, the patient remained asymptomatic and was able to lead a normal life.
Discussion ▼ Erythromelalgia is commonly characterized by episodic erythema, warmth and burning pain in the extremities. We report on a 12-year-old boy who initially did not show this classical triad of symptoms -a fact that initially mistakenly lead us to arthritis as the primary diff erential diagnosis. In a retrospective case series of 168 patients, 34 % of patients were found to present with normal physical examination of the limbs [ 6 ] . The authors did not clarify the symptoms of the aff ected abnormal limb. Approximately 67 % of patients experienced pain relief with cold water, which in our case was the critical key to diagnosis. In children, a quarter of erythromelalgia patients present with normal clinical fi ndings upon examination and a monophasic course with full recovery is possible [ 4 ] . The pathophysiological mechanisms in erythromelalgia may be explained by a sensitization of polymodal C nociceptors -a state that could lower the temperature threshold for activation of C fi bers from a normal value to the lower level encountered by erythromelalgia patients. Thus, skin temperatures above threshold could trigger both the burning pain (from activated C fi bers) and vasodilation (via the axon refl ex mechanism). Vasodilation would keep the skin temperature elevated and sustain the symptoms until external cooling is applied. This said, cooling, especially via use of ice and ice water, should be used with caution, in order to avoid skin necrosis and ulcerations [ 6 , 16 ] . Additional management strategies therefore should include avoiding triggers of symptoms -i. e., extreme heat, dramatic changes in temperature, and over-exertion during exercise [ 17 ] . Pharmacological approaches to relieve pain or -even more diffi cult to achieve -freedom from pain are challenging, especially in the pediatric population. Despite progress in understanding the molecular and genetic cause of the disease, the complete pathophysiological sequence leading to pain is not yet fully understood. Primary erythromelalgia is the inherited form of erythromelalgia and represents a "channelopathy". It often runs in families, with an autosomal-dominant pattern of inheritance. Although the SCN9A gene, which codes for the α-subunit of sodium channel Na V 1.7, seems to be most commonly aff ected, other reports clearly exclude this gene locus [ 2 ] . Further potential candidate genes aff ected in the pathogenesis include additional sodium channel genes, such as SCN10A and SCN11A. Spontaneous mutations are most likely responsible for the sporadic cases that occur without family history; nevertheless, treatment strategies should not be dependent upon positive genetic fi ndings. Secondary erythromelalgia is defi ned as erythromelalgia that is related to another underlying disease. The most common diseases associated with erythromelalgia are essential thrombocytopenia, polycythemia vera, myeloproliferative disorders, various rheumatic diseases (such as systemic lupus erythematodes), diabetes and medications. All of the above were able to be excluded in our patient. It is hypothesized that sodium nitroprusside is eff ective because erythromelalgia symptoms may be caused by tissue hypoxia that has been induced by impairment of microvascular blood fl ow through arteriovenous shunting. Nitroprusside has a potent vasodilating eff ect, in arterioles more so than in venules, which may redistribute the reduced blood fl ow. Reports of nitroprusside's successful use have been documented, including in relation to the pediatric population [ 3 , 14 , 21 ] . However, nitroprusside's clinical benefi t has been controversial and our patient did not show any pain alleviation with the use of it. An explanation for the failure of nitroprusside may be deduced from the fact that our patient presented with severe pain but no swelling or redness of the aff ected extremities, indicating only a minor degree of arteriovenous shunting. The disturbed microvascular blood fl ow pattern, secondary to biophysical sodium channel alterations, may not contribute to pain in all patients. It is probable that such patients do not respond to nitroprusside.
The literature includes several promising reports regarding the benefi ts provided by sodium channel blockers in the treatment of erythromelalgia [ 16 , 18 , 20 ] . By stabilizing the membrane in neurons, depolarization and permeability are inhibited, slowing down the peripheral nerve conduction. Lidocaine, applied intravenously, and oral mexiletine, both class IB antiarrhythmia drugs and from the same substance class, have been used successfully for the treatment of neuropathic pain [ 1 , 8 , 22 ] . Most case reports of successful pain reduction in erythromelalgia patients began treatment with intravenous lidocaine and subsequently switched to oral mexiletine [ 16 , 18 , 20 ] . The eff ectiveness of intravenous lidocaine in producing analgesia in neuropathic pain seems to be a predictor of the following effi cacy of oral mexiletine [ 12 ] . In a recent report by Iqbal et al. regarding 2 adult patients, mexiletine was initiated without prior use of lidocaine and both patients showed signifi cant improvement of symptoms [ 15 ] . This strategy may be successful in shortening the duration of hospitalization. Nevertheless, pain relief is not predictable with the use of sodium channel blockers. It should be emphasized that erythromelalgia patients suff er from severe pain with substantial morbidity and even mortality [ 4 ] . Therefore, despite pain alleviation in our patient under lidocaine treatment, we started oral gabapentin in parallel with oral mexiletine. McGraw et al. report gabapentin's eff ectiveness in pain relief in 2 erythromelalgia patients [ 19 ] . Additional therapeutic interventions, such as regional anesthetic blockade [ 13 ] , were not necessary in our patient. In summary, we report on a 12-year-old boy with new-onset primary non-inherited erythromelalgia, which may have been associated with small-fi ber neuropathy. Standard analgetic therapy with peripherally acting analgesics and opioids in addition to sodium nitroprusside had no eff ect on pain. Sodium channel blockers -lidocaine and mexiletine -combined with gabapentin and additional psychological support, led to resolution of all symptoms. Despite improved understanding of the molecular aspect of this disease, pain management in these patients is challenging -particularly in children -given the absence of controlled therapeutic studies. Due to the rare occurrence of the disease in children, such studies should be performed collaboratively.
